{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:04:57Z","timestamp":1793109897566,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,13]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pyoderma gangrenosum (PG) is a neutrophilic skin disease characterized by recurrent painful cutaneous ulcers, often accompanied by inflammatory bowel disease, joint pain, and other systemic damage. This disease is relatively rare in clinical practice and its diagnosis and treatment are often delayed, leading to secondary infections in the skin lesions, prolonged disease course, and increased disease burden on patients. This study retrospectively analyzed the clinical characteristics and treatment strategies of patients with PG admitted to our hospital and conducted a literature review, in order to improve the understanding of the disease among clinical doctors, enable patients to receive better diagnosis and treatment, and ultimately improve patient prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Clinical data of patients diagnosed with PG and hospitalized in Beijing Chaoyang Hospital, Capital Medical University from January 2014 to December 2022 were retrospectively collected. The clinical manifestations, treatment strategies, efficacy, and disease outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 14 patients, including 8 males and 6 females, aged 14 to 66 years, were included. Skin lesion types: 13 cases were ulcer-type, 1 case was pustule combined with ulcer-type, and the lower limbs were the most commonly affected areas. All the 14 patients presented with comorbidities. All patients were treated with glucocorticoids, with a daily dose equivalent to 20 to 100\u2009mg prednisone and a median dose of 40\u2009mg. Among them, 3 patients were treated with minocycline in combination, 1 patient was treated with mycophenolate mofetil 0.5 twice daily in combination, 1 patient was treated with cyclophosphamide 0.1 once daily in combination, and 1 patient was treated with thalidomide 0.1 every night in combination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>PG is a relatively rare immune-related skin disease. Our small sample data analysis found that male PG is not uncommon in the Chinese population. Systemic glucocorticoids can quickly control the symptoms of PG in most patients with PG. In patients with poor efficacy or limited use of glucocorticoids, immunosuppressive drugs or novel targeted drugs such as biologics or small-molecule drugs should be used in combination as early as possible. Skin lesion care focuses on preventing infection, avoiding surgical debridement, and emphasizing pain management and the symptomatic treatment of comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000039634","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T13:18:13Z","timestamp":1726579093000},"page":"e39634","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Clinical characteristics of pyoderma gangrenosum: Case series and literature review"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7180-6962","authenticated-orcid":false,"given":"Rina","family":"Su","sequence":"first","affiliation":[{"name":"Department of Dermatology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiguang","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Chao-yang Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260203","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum.","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20260203","doi-asserted-by":"crossref","first-page":"224","DOI":"10.7861\/clinmedicine.19-3-224","article-title":"Pyoderma gangrenosum - a guide to diagnosis and management.","volume":"19","author":"George","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"R3-20260203","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2019.08.001","article-title":"Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis.","volume":"83","author":"Xu","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R4-20260203","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/jid.2012.130","article-title":"Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study.","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol"},{"key":"R5-20260203","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/iwj.12939","article-title":"Epidemiology of pyoderma gangrenosum: results from an Italian prospective multicentre study.","volume":"15","author":"Monari","year":"2018","journal-title":"Int Wound J"},{"key":"R6-20260203","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamadermatol.2017.5978","article-title":"The association of age with clinical presentation and comorbidities of pyoderma gangrenosum.","volume":"154","author":"Ashchyan","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R7-20260203","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40257-018-0356-7","article-title":"Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis.","volume":"19","author":"Kridin","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"R8-20260203","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bjd.14691","article-title":"Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation.","volume":"175","author":"Marzano","year":"2016","journal-title":"Br J Dermatol"},{"key":"R9-20260203","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-4632.2004.02128.x","article-title":"Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria.","volume":"43","author":"Su","year":"2004","journal-title":"Int J Dermatol"},{"key":"R10-20260203","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts.","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R11-20260203","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/ced.14809","article-title":"Anakinra for recalcitrant pyoderma gangrenosum.","volume":"46","author":"O\u2019Connor","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"R12-20260203","first-page":"1","article-title":"Off-label uses of TNF-a inhibitors and IL-12\/23 inhibitors in dermatology.","volume":"27","author":"Hong","year":"2021","journal-title":"Dermatol Online J"},{"key":"R13-20260203","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-024-05560-1","article-title":"Tofacitinib therapy for severe pyoderma gangrenosum in a patient with enteropathic arthritis: a case-based review.","author":"K\u00f6ken Av\u015far","year":"2024","journal-title":"Rheumatol Int"},{"key":"R14-20260203","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments.","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"R15-20260203","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-023-01931-3","article-title":"Pyoderma gangrenosum: treatment options.","volume":"83","author":"Dissemond","year":"2023","journal-title":"Drugs"},{"key":"R16-20260203","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/1346-8138.17031","article-title":"New treatment of pyoderma gangrenosum and hidradenitis suppurativa: a review.","volume":"51","author":"Yamanaka","year":"2024","journal-title":"J Dermatol"},{"key":"R17-20260203","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1089\/wound.2020.1168","article-title":"A wound care specialist\u2019s approach to pyoderma gangrenosum.","volume":"9","author":"Croitoru","year":"2020","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"R18-20260203","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaad.2021.09.053","article-title":"Wound care dressings for pyoderma gangrenosum.","volume":"86","author":"Strunck","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R19-20260203","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-017-0251-7","article-title":"Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment.","volume":"18","author":"Alavi","year":"2017","journal-title":"Am J Clin Dermatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:01:11Z","timestamp":1770138071000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":19,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039634","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]}}}